The present invention is directed to a protein kinase inhibitor for use in the treatment of tuberculosis, by direct inhibition of the growth of a Mycobacterium tuberculosis complex species, and to corresponding methods of treating tuberculosis. More specifically, the invention relates to the use of protein tyrosine kinase inhibitors such as gefitinib, erlotinib, or imatinib for use in the treatment of tuberculosis, by direct inhibition of the growth of a Mycobacterium tuberculosis complex species, rather than through use in host-directed therapy. Also provided are methods of determining the ability of a protein tyrosine kinase inhibitor to inhibit the growth of a Mycobacterium tuberculosis complex species and methods of identifying a protein tyrosine kinase inhibitor as being potentially effective in the treatment of tuberculosis by direct inhibition of a Mycobacterium tuberculosis complex species.
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61P 31/06 - Antibacterial agents for tuberculosis
The United States Government as Represented by The Department of Veteran Affairs (USA)
Inventor
Chen, Yijiang
Madabhushi, Anant
Barisoni, Laura
Abstract
The present disclosure relates to a method. The method includes accessing a digitized pathology image stored in a memory. The digitized pathology image is from a glomerular disease patient. A plurality of peritubular capillary (PTC) features are extracted from the digitized pathology image. The plurality of PTC features include a plurality of PTC spatial architecture features and a plurality of PTC shape features. The plurality of PTC features are provided to a machine learning stage. The machine learning stage is configured to generate a medical prediction relating to glomerular disease based upon the plurality of PTC features.
G06V 10/25 - Determination of region of interest [ROI] or a volume of interest [VOI]
G06V 10/26 - Segmentation of patterns in the image fieldCutting or merging of image elements to establish the pattern region, e.g. clustering-based techniquesDetection of occlusion
G06V 10/44 - Local feature extraction by analysis of parts of the pattern, e.g. by detecting edges, contours, loops, corners, strokes or intersectionsConnectivity analysis, e.g. of connected components
3.
Inducing Proliferation of Cardiomyocytes and Therapeutic Uses Related Thereto
This disclosure relates to methods of treating or preventing heart malformations or cardiovascular diseases comprising administering an effective amount of thyroid hormone in combination with i) an agent that decreases DUSP5 and/or DUSP6 expression and/or ii) a beta-adrenergic blocking agent to a subject in need thereof. In certain embodiments, this disclosure relates to in vivo and in vitro methods of inducing proliferation of cardiomyocytes using agents or combinations of agents disclosed herein.
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
Disclosed herein is a tracer compound N-(2-((2S,4S)-2-cyano-4-[18F]fluoropyrrolidin-1-yl)-2-oxoethyl)quinoline-4-carboxamide, derivative, or salt thereof and uses as an imaging and/or therapeutic agent. In certain embodiments, this disclosure relates to precursor compounds such as (3R,5S)-5-cyano-1-((quinoline-4-carbonyl)glycyl)pyrrolidin-3-yl-4-nitrobenzenesulfonate, derivative, or salt thereof and kits comprising the same.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
5.
Cardiac Valve Leaflet Enhancer Devices and Systems
The disclosure relates to a device that is configured to be implanted on the native leaflet of a heart valve to increase its length and/or thickness and thereby to improve the valve function and reduce regurgitation. The device may include a leaflet section. The leaflet section may include a central member. The central member may include a first portion, a second portion that opposes the first portion, and a base portion disposed between the first portion and the second portion. The first section may extend from the first portion and the second section may extend from the second portion. The device may include one or more engaging members extending from the central member at an angle with respect to the first section and the second section. The second section may be larger than the first section. The leaflet section may define a three-dimensional region or a bulge.
This disclosure relates to methods of treating, preventing, or reversing inflammation-associated central nervous system (CNS) disorders or conditions comprising administering an effective amount of a Janus kinases (JAK) inhibitor such as baricitinib to a patient in need thereof. In certain embodiments, the CNS associated inflammatory disorder is depression, treatment resistant depression, fatigue, or cognitive dysfunction.
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/529 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
This disclosure relates to compounds, pharmaceutical compositions, and methods of treating or preventing sickle cell disease or conditions associated thereto. In certain embodiments, the compounds are 1-(thiazol-2-yl)urea derivatives. In certain embodiments, the compounds are 1-(9H-carbazol-9-yl)-3-mercaptopropan-2-ol derivatives. In certain embodiments, the compounds are 1-phenyl-1H-pyrrole-2,5-dione derivatives. In certain embodiments, this disclosure relates to methods of treating or preventing sickle cell disease or condition associated thereto comprising administering an effective amount of a 1-(thiazol-2-yl)urea derivative, or 1-phenyl-1H-pyrrole-2,5-dione derivative, or a 1-(9H-carbazol-9-yl)-3-mercaptopropan-2-ol derivative as disclosed herein to a subject in need thereof.
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
C07D 207/416 - 2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
C07D 207/448 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
C07D 209/38 - Oxygen atoms in positions 2 and 3, e.g. isatin
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
8.
N-Cyclopropyl-1-(4-(4-(Fluoro-18f)Phenyl)Pyrimidin-5-Yl)-N-Methylpiperidine- 4-Carboxamide and Uses in PET Imaging
Disclosed herein is a PET tracer compound N-cyclopropyl-1-(4-(4-(fluoro-18F) phenyl)pyrimidin-5-yl)-N-methyl piperidine-4-carboxamide or salt thereof, and uses as an imaging agent. In certain embodiments, this disclosure relates to precursor compounds such as N-cyclopropyl-N-methyl-1-(4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) phenyl)pyramidin-5-yl)piperidine-4-carboxamide or salt thereof and kits comprising the same.
C07B 59/00 - Introduction of isotopes of elements into organic compounds
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
This disclosure relates to devices and methods for signaling surface concentrations of biomolecules on particles or other surfaces. In certain embodiments, this disclosure contemplates methods for detecting surface concentrations of biomolecules on a cell or other particle separated by a distance comprising contacting a particle comprising multiple antigens on the surface of the particle with a nucleobase polymer complex comprising a first aptamer domain, a second aptamer domine, and a double stranded reporter domain.
C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
09 - Scientific and electric apparatus and instruments
41 - Education, entertainment, sporting and cultural services
Goods & Services
Downloadable podcasts in the field of public health Educational and entertainment services, namely, a continuing program about public health topics accessible via podcast, radio, audio, video and computer networks; Entertainment services, namely, providing podcasts in the field of public health topics; Providing information, news and commentary in the field of current events relating to public health
11.
HPV Proteins, Antibodies, and Uses in Managing Abnormal Epithelial Cell Growth
This disclosure relates to HPV proteins, antibodies, and uses in managing abnormal epithelial cell growth. In certain embodiments, this disclosure relates to detecting an HPV protein in a sample and correlating the presence as an indication that a subject is at risk of developing an HPV-related disease or condition. In certain embodiments, the HPV protein is E2 and/or E6. In certain embodiments, this disclosure relates to vaccinating or treating a subject for an HPV infection or related condition optionally in combination with immune-checkpoint inhibitors. In certain embodiments, this disclosure relates to HPV protein specific antibodies and binding agents for uses reported herein.
The present disclosure is generally related to methods for combining chemotherapy and immunotherapy for the treatment of a cancer. The methods also relate to generating a drug- resistant cytotoxic immune cell line and uses thereof in conjunction with cytotoxic drugs.
A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
A61K 40/15 - Natural-killer [NK] cellsNatural-killer T [NKT] cells
Disclosed are purine nucleotide and nucleoside therapeutic compositions therapeutic compositions and uses related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections. Such viral infections can include enterovirus, tongaviridae, bunyaviridae, arenaviridae, coronaviridae, flaviviridae, picornaviridae, Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infections.
C07H 19/173 - Purine radicals with 2-deoxyribosyl as the saccharide radical
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
14.
Modulators of Orphan Nuclear Receptors for Treating Pancreatitis, Glioblastoma, Sarcopenia and Stroke
Compounds, compositions and methods for modulating retinoic acid receptor-like orphan receptors (ROR) so as to increase FGF21 levels, and treating and preventing disorders associated with FGF21, such as pancreatitis, sarcopenia, stroke, and traumatic brain injury, and to increase miR-122 levels, and treating and preventing disorders such as glioblastoma.
INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (Republic of Korea)
Inventor
Yoon, Young-Sup
Lee, Shin-Jeong
Jun, Ho-Wook
Abstract
This disclosure relates to methods of generating endothelial cells derived from stem cells. In certain embodiments, the cells are useful for inducing vasculature in muscles and cardiac tissue. In certain embodiments, the disclosure relates to methods of transforming pluripotent or multipotent stem cells, such as embryonic or induced pluripotent stem cells, into endothelial cells derived therefrom using a GSK3 inhibitor and/or delta like canonical notch ligand 4 (DLL4).
A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
16.
Phosphate Membrane Nanodiscs Conjugated to Therapeutic Agents and Medical Uses Thereof
This disclosure relates to phosphate membrane nanodiscs covalently modified with therapeutic agents such as antisense oligonucleotides or other nucleobase polymers and medical uses related thereto. In certain embodiments, the phosphate membrane nanodiscs comprise a phospholipid having a thiol group used for conjugation to agents such as oligonucleotides or other nucleobases polymers having a thiol reactive group. In certain embodiment, the phosphate membrane nanodiscs comprise a stabilizing peptide having a thiol group used for further conjugation to therapeutic agents.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
Disclosed herein are methods of evaluating the spatial distribution of lipid nanoparticles containing various concentrations of chemical components in tissues or cells using nucleic acid barcodes. In certain embodiments, the methods entail administering a group of lipid nanoparticles that contain nucleic acids that encode a cell surface antigen and barcodes that are correlated to the chemical components of the lipid nanoparticles. The lipid nanoparticles in the tissues of a subject are evaluated for the content of the nucleic acid barcodes at various fixed locations and recorded on a computer readable medium.
UNIVERISTY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventor
Dai, Mingji
Al-Ahmad, Reem
Ma, Donghui
Khanna, Rajesh
Abstract
Disclosed herein are compounds that are veragranine analogs, pharmaceutical compositions, and medical uses thereof. In certain embodiments, this disclosure relates to pharmaceutical compositions comprising a compound as disclosed herein and a pharmaceutically acceptable excipient. In certain embodiments, this disclosure relates to methods of treating pain or other inflammatory condition comprising administering an effective amount of a compound disclosed herein to a subject in need thereof.
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
Disclosed herein are methods of decreasing mucus hypersecretion in the lungs comprising administering an effective amount of a MUC1 inhibitor to a subject in need thereof. In certain embodiments, the MUC1 inhibitor is the peptide GO-201, GO-203, or GO-203-2C. In certain embodiments, the subject is a human patient. In certain embodiments, the subject is diagnosed with rhinosinusitis, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, bronchiectasis, asthma, idiopathic pulmonary fibrosis, acute respiratory distress syndrome (ARDS), cystic fibrosis, or a respiratory syncytial virus (RSV) infection.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 9/00 - Medicinal preparations characterised by special physical form
A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
20.
HAPTICALLY-ENABLED FOOT ANKLE ORTHOSIS FOR POST-INJURY PLANAR PRESSURE MONITORING AND MODULATION
An exemplary embodiment of the present disclosure provides a haptic feedback device, comprising one or more pressure sensors and a haptic feedback sleeve. The one or more pressure sensors can be configured to measure a pressure applied to the foot of a user. The haptic feedback sleeve can be configured to provide haptic feedback to the user. The haptic feedback can be based, at least in part, on the pressure applied to the foot of the user.
A61F 5/01 - Orthopaedic devices, e.g. long-term immobilising or pressure directing devices for treating broken or deformed bones such as splints, casts or braces
21.
LIVER RECEPTOR HOMOLOG-1 (LRH-1) ANTAGONISTS AND USES THEREOF
This disclosure relates to liver receptor homolog-1 (LRH-1) antagonists and methods of using the same. The LRH-1 antagonists are useful for treating or preventing cancer, including breast cancer, colon cancer, gastric cancer, liver cancer, and pancreatic cancer. Also provided herein are methods of reducing LRH-1 activity in a cell, the method including contacting the cell with an effective amount of an LRH-1 antagonist.
C07C 13/11 - Monocyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with a five-membered ring with a cyclopentane ring substituted by unsaturated hydrocarbon groups
C07C 13/12 - Monocyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with a five-membered ring with a cyclopentene ring
C07C 43/205 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring the aromatic ring being a non-condensed ring
C07C 311/00 - Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
22.
LIVER RECEPTOR HOMOLOG-1 (LRH-1) AGONIST ISOSTERES AND USES
This disclosure relates to a series of small molecule agonists that mimic liver receptor homolog-1 (LRH-1). The compounds display exceptional potency and efficacy. Also disclosed are pharmaceutical compounds and methods of treating or preventing various conditions including cancer, cardiovascular disease, diabetes, colitis, or ulcerative colitis. Further disclosed are methods of modulating activity of LRH-1 in cells.
Disclosed herein are compositions comprising a vector encoding PD-L1 or fragment thereof and methods of use. In certain embodiments, the vector further encodes a peptide based therapeutic or binding agent. In certain embodiments, the compositions are used in methods of treating or preventing diseases or conditions that utilize peptide base therapeutics such as anti-viral, anti-HIV, anti-inflammatory, or anti-cancer antibodies.
The disclosure relates to a device that is configured to be implanted on the native leaflet of a heart valve to increase its length and/or thickness and thereby to improve the valve function and reduce regurgitation. The device may include a leaflet section. The leaflet section may include a central member. The central member may include a first portion, a second portion that opposes the first portion, and a base portion disposed between the first portion and the second portion. The first section may extend from the first portion and the second section may extend from the second portion. The device may include one or more engaging members extending from the central member at an angle with respect to the first section and the second section. The second section may be larger than the first section. The leaflet section may define a three-dimensional region or a bulge.
The present disclosure relates to a three-dimensional structure including an inverted co-culture having an interior layer comprising a plurality of cells of a first cell type; an opposing exterior layer comprising a plurality cells of a second cell type; and a basement membrane matrix positioned between the interior layer and the exterior layer, wherein the three-dimensional structure has a diameter, and wherein said diameter is capable of being altered by an alloimmune reaction that disrupts the plurality of cells of the second cell type and leads to contraction of the plurality of cells of the second cell type. Also disclosed is a method of modeling Bronchiolitis Obliterans Syndrome, a method for assessing presence of or risk of developing a physiological condition, a method of identifying one or more biomarkers of a disease, and a method of a method of making a three-dimensional structure.
The present disclosure relates to methods and compositions comprising a universal cell delivery ligand configured to enhance the intratumoral delivery and distribution of therapeutic immune cells by facilitating their penetration through dense stroma surrounding tumor cells.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
In some embodiments, the present disclosure relates to a method that includes accessing digitized pathology imaging data from a cancer patient. The digitized pathology imaging data has been segmented to identify a plurality of cancer nuclei within one or more tumor regions. A plurality of nuclei diversity features are extracted using the plurality of cancer nuclei. The plurality of nuclei diversity features include a combination of shape features and second order features generated using the shape features. The plurality of nuclei diversity features are provided to a machine learning model that is trained to generate a medical prognosis regarding the cancer patient.
G06V 10/26 - Segmentation of patterns in the image fieldCutting or merging of image elements to establish the pattern region, e.g. clustering-based techniquesDetection of occlusion
Disclosed are VIP-R antagonists for uses in managing the treatment or prevention of cancer and viral infections. In certain embodiments, this disclosure relates to chimeric variants of VIP-R antagonists, as peptides disclosed herein, and pharmaceutical composition comprising the same. In certain embodiments, this disclosure contemplates methods of treating subjects with cancer or infection with VIP-R antagonists or stimulating immune cells to target cancer by mixing immune cells in vitro with peptides disclosed herein and further administering an effective amount of stimulated immune cells to a subject in need of cancer treatment.
In certain embodiments, this disclosure relates to method of treating and diagnosing cancer by administering a Bcl-2 inhibitor optionally in combination with a mitochondrial complex II inhibitor. In certain embodiments, a subject is diagnosed with, exhibiting symptoms of, or at risk of cancer wherein the cancer is a hematological malignancy such as multiple myeloma, leukemia, or lymphoma.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/02 - Antineoplastic agents specific for leukemia
31.
2'-FLUORO-6'-METHYLENE CARBOCYCLIC NUCLEOS(T)IDES AS POTENT ANTIVIRAL AGENTS FOR THE TREATMENT OF WILD-TYPE AND MUTANT HEPATITIS B VIRUS (HBV) INFECTIONS
C07D 473/34 - Nitrogen atom attached in position 6, e.g. adenine
C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
C07D 473/18 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
C07D 239/47 - One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
C07F 9/6512 - Six-membered rings having the nitrogen atoms in positions 1 and 3
C07D 239/54 - Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
C07D 249/10 - 1,2,4-TriazolesHydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Techniques are provided for determining a qualitative, quantitative and/or categorical assessment of one or more users and/or images with respect to one or more populations. The eye movement data of the user may be obtained with respect to each image of the one or more images displayed for a period of time. One or more memory performance measures and/or one or more salience performance measures may be determined using the eye movement data with respect to the one or more regions of the one or more images for one or more of predetermined time ranges of the period of time. The quantitative, qualitative and/or categorical assessment of the user and/or images presented may be determined with respect to one or more populations, using the one or more memory performance measures and/or one or more salience performance measures.
This disclosure relates to drug releasing implants. In certain embodiments, the implants release drugs from a biodegradable material. In certain embodiments, the implant is a low swelling hydrogel. In certain embodiments, the drug is an analgesic, an anti-inflammatory agent, anti-bacterial or other anti-microbial agent. In certain embodiments, this disclosure relates to methods of providing an implant as reported herein at a surgical site or site of injury for uses in reducing post operative pain and inflammation.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61L 27/18 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
In some embodiments, the present disclosure relates to a method. The method includes accessing digitized pathology imaging data from a cancer patient. The digitized pathology imaging data has been generated using immunohistochemical (IHC) stained pathology images and has been segmented to identify a plurality of immune cells. The plurality of immune cells are used to extract a plurality of immune cell features from the digitized pathology imaging data. The plurality of immune cell features are operated upon by a machine learning stage that is trained to generate a medical prognosis relating to the cancer patient.
The present disclosure, in some embodiments, relates to a method that includes accessing digitized pathology imaging data of tissue excised from a cancer patient. The digitized pathology imaging data has been segmented to identify one or more of glandular regions, immune cells, and invasive cribriform adenocarcinoma (ICC). A plurality of features are extracted from the digitized pathology imaging data. The plurality of features include one or more of immune cell spatial features, glandular morphometric features, and ICC area features. The plurality of features are provided to a machine learning model that is trained to generate a medical prognosis for the cancer patient using the plurality of features.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
The present disclosure, in some embodiments, relates to a method. The method includes accessing one or more digitized three-dimensional (3D) pathology images of glandular tissue from a cancer patient. One or more 3D gland models are generated using the one or more digitized 3D pathology images. A plurality of glandular architecture features are extracted from the one or more 3D gland models. The plurality of glandular architecture features are provided to a machine learning model that has been trained to generate a medical prognosis for the cancer patient.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G06T 7/33 - Determination of transform parameters for the alignment of images, i.e. image registration using feature-based methods
G06T 7/174 - SegmentationEdge detection involving the use of two or more images
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 70/20 - ICT specially adapted for the handling or processing of medical references relating to practices or guidelines
This disclosure relates to methods of treating a coronavirus infection or other microbial infection comprising administering an effective amount of a plant extract, or compound, or combination of compounds derived therefrom to a subject in need thereof. In certain embodiments, the plant extract is obtained by a process of contacting a segment of a plant a with a solvent providing an extract as reported herein. In certain embodiments, this disclosure contemplates pharmaceutical compositions comprising extracts and components contained therein for use in methods of treating viral or other microbial infections.
In some embodiments, the present disclosure relates to a method. The method includes accessing digitized pathology imaging data from a cancer patient. The digitized pathology imaging data includes segmented imaging data that identifies one or more regions of interest (ROI) including tumor-stroma regions and/or collagen fibers. A plurality of collagen fiber features are extracted from the one or more ROI. The plurality of collagen fiber features are provided to a machine learning model that is trained to generate a medical prognosis relating to the cancer patient.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G06T 7/73 - Determining position or orientation of objects or cameras using feature-based methods
G06V 10/25 - Determination of region of interest [ROI] or a volume of interest [VOI]
G06V 10/44 - Local feature extraction by analysis of parts of the pattern, e.g. by detecting edges, contours, loops, corners, strokes or intersectionsConnectivity analysis, e.g. of connected components
Disclosed herein are pharmaceutical compositions for the treatment of respiratory diseases and disorders, including rhinosinusitis. In some aspects, the compositions provide selective delivery to the upper airway and facilitate the transport active agents effectively across membranes.
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/549 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
A61K 31/54 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame
This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether. The nucleotide and nucleoside therapeutic compositions can include at least one second antiviral agent, such as an antiviral agent that treats or prevents enterovirus infections.
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 31/09 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
CHRISTIAN MEDICAL COLLEGE ASSOCIATION, VELLORE (India)
INSTITUTE FOR STEM CELL SCIENCE AND REGENERATIVE MEDICINE (India)
EMORY UNIVERSITY (USA)
CHILDREN'S HEALTHCARE OF ATLANTA INC (USA)
Inventor
Srivastava, Alok
Spencer, Harold Trent
Doering, Christopher
Singh, Gurbind
Shaji, Ramachandran Velayudhan
Denning, Gabriela Bout
Lollar, John S.
Abstract
Aspects of the present disclosure are directed to a gene therapy approach for treating bleeding disorders, in particular Haemophilia comprising transduction of autologous hematopoietic stem and progenitor cells (HSPCs) with lentiviral viral vectors for expression of blood clotting factors to correct their deficiency in these disorders. The invention further discloses a process and formulation comprising transduced cells for the administration to patients, preferably with bleeding disorders, in particular preceded by a conditioning regimen.
Aspects of the present disclosure are directed to a gene therapy approach for treating bleeding disorders, in particular Haemophilia comprising transduction of autologous hematopoietic stem and progenitor cells (HSPCs) with lentiviral viral vectors for expression of blood clotting factors to correct their deficiency in these disorders. The invention further discloses a process and formulation comprising transduced cells for the administration to patients, preferably with bleeding disorders, in particular preceded by a conditioning regimen.
The disclosure also describes myeloablative, non-myeloablative or non-genotoxic conditioning regimens, for preparing the patient for transplantation with formulation of the invention.
A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
A61K 31/255 - Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
This disclosure relates to heteromultivalent nucleic acid-functionalized surfaces, such as particles, and uses in optimizing hybridization specificity for targets containing one, two, or more mutations. In certain embodiments, heteromultivalent hybridization enables fine-tuned specificity for a single SNP and dramatic enhancements in specificity for two non-proximal SNPs empowered by cooperative binding. In certain embodiments, use of specified oligo lengths, spacer lengths, and binding orientation are contemplated. In certain embodiments, this disclosure provides for methods of discrimination between heterozygous cis and trans mutations and between different strains of a virus, e.g., the SARS-CoV-2 virus.
C12Q 1/6834 - Enzymatic or biochemical coupling of nucleic acids to a solid phase
C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
44.
NETWORK ANALYSIS OF THE CEREBROSPINAL FLUID PROTEOME OF SPORADIC AND FAMILIAL FORMS OF AMYOTROPHIC LATERAL SCLEROSIS AND METHODS OF TREATMENT OF THE SAME
In one aspect, the disclosure relates to methods for diagnosing a neurodegenerative disease associated with loss of motor neurons such as, for example, amyotrophic lateral sclerosis (ALS). In a further aspect, the disclosed method can also be used to distinguish between ALS subtypes In an aspect, the method involves obtaining a sample of cerebrospinal fluid or another biological sample from a patient, contacting the sample with one or more enzymes capable of C-terminal and/or N-terminal cleavage of lysine and/or arginine, and analyzing the cleaved proteins using mass spectrometry, including comparison of the cleaved proteins to one or more databases and quantifying the cleaved proteins in order to diagnose the neurodegenerative disease and identify the subtype of the neurodegenerative disease. Also disclosed are methods for treating ALS using antisense oligonucleotides (ASOs).
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61P 25/00 - Drugs for disorders of the nervous system
C12Q 1/37 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving peptidase or proteinase
45.
Particles with RNA Cleaving Nucleobase Polymers and Uses for Managing Inflammatory Disorders
The United States Government as represented by the Department of Veterans Affairs (USA)
Inventor
Salaita, Khalid
Wongtrakool, Cherry
Galior, Kornelia
Abstract
This disclosure relates to nucleobase polymers useful for degrading GATA-3 mRNA. In certain embodiments, this disclosure relates to nucleobase polymers and nanoparticles conjugated to nucleobase polymers disclosed herein. In certain embodiments, the nucleobase polymers or nanoparticles can be used in methods of managing disorders associated with excessive GATA-3 expression in inflammatory disorders and respiratory disorders such as asthma.
B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
46.
CYTOKINE THERAPIES FOR MANAGING HIV AND OTHER VIRAL INFECTIONS
Disclosed herein are methods of treating HIV comprising administering an effective amount of IL-15 and/or IL-15Ralpha optionally in combination with IL-12 or nucleic acids or vectors encoding the same to a human patient in need thereof. In certain embodiments, the IL-15 and/or IL-15Ralpha optionally in combination with IL-12 or nucleic acids or vector encoding the same are administered in combination with a multi-drug anti-retroviral therapy (ART).
In some embodiments, the present disclosure relates to a method. The method includes accessing an instance matrix having a plurality of instance values and a configuration vector having a configuration values. Iterations are performed on a computing apparatus to determine an optimized configuration vector. The iterations respectively include simultaneously determining a plurality of reduction values by multiplying the configuration values by instance values within a row of the instance matrix. A plurality of fitness values are respectively determined using the plurality of reduction values and configuration value associated with a row of the instance matrix. A current cost is determined by summing the plurality of fitness values. Unstable fitness values are simultaneously identified based upon a comparison of the plurality of fitness values with a threshold. At least one of the configuration values associated with the unstable fitness values are simultaneously updated based upon a probabilistic selection.
The present disclosure relates to systems and methods for preventing aspiration. In one implementation, the systems may include devices that can be used during gastrointestinal (GI) endoscopic procedures to prevent pulmonary aspiration and avoid esophageal pinch injury. The device may include a tube including a central lumen disposed along its length. The central lumen may be configured to receive an instrument. The device may include an occluder disposed at an end and including a lumen along its length. The occluder may have an outer surface that extends between a first circumference at its first end and a third circumference at its second end and a lumen that extends between the first circumference and the second circumference at its second end. The occluder may be configured to reversibly collapse to one or more collapsed configurations with respect to the tube. The occluder may be biased to an expanded configuration.
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
49.
Multifunctional Nanoparticles and Uses in Managing Cancer and Cardiovascular Diseases
This disclosure relates to nanoparticles comprising a cardiovascular agent, a PD-L1 binding agent on the surface, and optionally an anticancer agent. In certain embodiments, the cardiovascular agent is an inhibitor of cholesterol acyltransferase such as avasimibe. In certain embodiments, the nanoparticles comprise a hyaluronic acid core. In certain embodiments, this disclosure relates to methods of treating or preventing cancer and/or atherosclerosis, or other cardiovascular disease by administering an effective amount of nanoparticles disclosed herein to a subject in need thereof.
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 31/475 - QuinolinesIsoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
50.
THIAZEPINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES IN MANAGING RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR RELATED DISEASES AND CONDITIONS
HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (Israel)
Inventor
Schinazi, Raymond
Amblard, Franck
Kasthuri, Mahesh
Tber, Zahira
Galun, Eithan
Layani, Shanny
Amran, Osher
Abstract
Disclosed herein are heterocyclic compounds that modulate retinoic acid receptor-related orphan receptors and uses in managing related diseases and conditions. In certain embodiments, the heterocyclic compounds are thiazepine derivatives or 11-oxodibenzo[b,f][1,4]thiazepine derivatives. In certain embodiments, this disclosure relates to pharmaceutical compositions comprising compounds disclosed herein for uses reported herein.
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
C07D 417/02 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings
This disclosure relates to compositions and uses of caged proteins substituted with a photon decomposing chemical structure wherein the photon decomposing chemical structure is substituted through a linking group to a hydrophilic polymer. In certain embodiments, the caged protein is a proteinaccous agent such as an anticancer agent, cytokine, interleukin, fragment, or fusion thereof.
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
The University of North Carolina at Chapel Hill (USA)
Inventor
Pandarinath, Chethan
Zhu, Feng
Kaufman, Matthew Tyler
Sedler, Andrew Robert
Giovannucci, Andrea
Abstract
The present disclosure provides novel training systems and methods for recurrent neural network models. One such method comprises obtaining a first sequence of sparse input data as training data; augmenting the first sequence of sparse input data by zero-filling missing input points; training the recurrent neural network model using the augmented sequence of sparse input data to obtain a trained recurrent neural network model, and applying new data as an input to the trained recurrent neural network model, wherein the new data comprises a second sequence of sparse input data to obtain a corresponding output data sequence.
Compositions and methods including synthetic delivery systems that utilize polynucleotides are provided. Polynucleotides disclosed herein can, for example, facilitate binding, uptake, nuclear trafficking, and/or genomic integration of a component of the synthetic delivery system, for example, a cargo.
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
Methods for predicting mutations in viruses, such as Coronaviruses, upon exposure to antiviral drugs, are disclosed. Mutated, non-naturally occurring viruses including those mutations, and methods of treatment with drugs that remain effective against the mutated viruses, are disclosed. These predictive methods can be useful in properly treating Covid patients with small molecule antiviral compounds that are effective against the particular SARS-COV-2 variant infecting the patient.
Devices, systems, arid methods are provided for securing communication integrity. An. input Signal associated with a user using a remote connection to access a client server can be received. The input signal may identify an. input received via an interface. An. integrity module can be executed to generate an integrity certificate using the input signal, a secret key, and a sequential identifier corresponding to the input The integrity certificate can be generated for use during a verification process associated with the input signal. The integrity certificate and the input signal can be transmitted to the client server using one or more channels. The client server can forward the integrity certificate and the input signal to a verification server configured to validate the integrity certificate.
H04L 9/32 - Arrangements for secret or secure communicationsNetwork security protocols including means for verifying the identity or authority of a user of the system
56.
APPLICATION OF ARTIFICIAL INTELLIGENCE FEATURES IN CANCER PATIENTS
In some embodiments, the present disclosure relates to a method. The method includes accessing digitized pathology imaging data from a cancer patient. The digitized pathology imaging data identifies cancer nuclei within one or more tumor regions. A plurality of features are extracted from the digitized pathology imaging data. The plurality of features are extracted using nuclei angularity measurements of respective ones of the cancer nuclei. The plurality of features are provided to a machine learning model that has been trained to generate a medical prediction corresponding to the cancer patient.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
An MRI-compatible robot including one or more fiducial markers, a first planar stage having a first joint configured to receive a surgical tool and a first mechanism configured to move the surgical tool, and a second planar stage having a second joint configured to receive the surgical tool and a second mechanism configured to move the surgical tool, wherein the second planar stage is generally parallel with the first planar stage.
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
A61M 5/42 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests having means for desensitising skin, for protruding skin to facilitate piercing, or for locating point where body is to be pierced
This disclosure relates to sensing the movement of DNA rolling motors comprising microparticles or rods on transduction material in the presence of viruses, microbes, or other analytes for diagnostic testing. In certain embodiments, the presence of viral particles, other target microbial biomolecules, or analytes stall the motor by specifically binding to aptamers crosslinking the analytes to the particles, rods, or surface of the transduction material. It is contemplated that microparticles or other rolling motors move along a surface whereby an aptamer targets an analyte, e.g., viral SARS-CoV-2, and acts to inhibit, reduce, or restrict the speed, acceleration, or area of movement on the surface indicating the presence of the analyte in the sample.
G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
G06V 10/75 - Organisation of the matching processes, e.g. simultaneous or sequential comparisons of image or video featuresCoarse-fine approaches, e.g. multi-scale approachesImage or video pattern matchingProximity measures in feature spaces using context analysisSelection of dictionaries
G06V 20/40 - ScenesScene-specific elements in video content
G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
59.
PNEUMATIC COMPRESSION VEST DEVICE, METHOD, AND SYSTEM FOR TRANSTHORACIC MANIPULATION FOR OXYGENATION
An exemplary method and pneumatic vest system (also referred to herein as a V/Q vest) are disclosed for improving oxygenation that can reproduce the effects of proning treatment. The exemplary pneumatic vest can be used synergistically with proning, as a replacement therapy for proning treatment, and/or to monitor or assess whether patients would respond well to a proning treatment. The exemplary pneumatic vest can be integrated with sensors and intubation equipment. The compression vest system can integrate a mechanical ventilator with a pneumatic compression vest to improve oxygenation, provide potential alternative or bridge to proning patients, and/or reduce mechanical ventilatory morbidity.
The disclosure relates to Prostaglandin receptor EP2 antagonists, derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing conditions and diseases in which EP2 receptor activation has a physiological role, such as but not limited to, brain injury, inflammatory diseases, epilepsy, neuroinflamation after a seizure, pain, endometriosis, cancer, rheumatoid arthritis, skin inflammation, vascular inflammation, colitis, and neurological disorders by administering a pharmaceutical composition comprising a compound disclosed herein to a subject in need thereof.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
Therapies comprising administering at least one antiviral nucleoside, and the use of such therapies in the treatment of viral infections, such as infection by Eastern equine encephalitis virus, Western equine encephalitis virus, Venezuelan equine encephalitis virus, Chikungunya virus, Ross River virus, orthomyxoviridae virus, paramyxoviridae virus, RSV, influenza A virus, influenza B virus, filoviridae virus, human coronavirus, SARS-CoV-1, MERS-CoV, SARS-CoV-2, Ebola virus, or Zika virus, are disclosed herein.
A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A system and a method for measuring deformability of red blood cells in microfluidic channels are disclosed. The system comprises one or more devices having one or more microfluidic channels with at least one cross-sectional dimension and configured to allow deformation of red blood cells of a blood sample to flow through the one or more microfluidic channels. Further, at least one imager is configured to generate a sequence of digital holography images or videos of the red blood cells of the blood sample transiting through the one or more microfluidic channels. Further, the system includes at least one processor that is operationally coupled to the at least one imager. The at least one processor is configured to analyze the generated sequence of digital holography images or videos to quantify and characterize deformability of the red blood cells within the one or more microfluidic channels.
G01N 15/01 - Investigating characteristics of particlesInvestigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
63.
SYSTEMS AND METHODS TO MEASURE OCCLUSION OF BLOOD CELLS IN MICROFLUIDIC CHANNELS
A system and a method for measuring occlusion of blood cells flowing in microfluidic channels is disclosed. The system includes an occlusion device having one or more microfluidic channels with a predefined cross-sectional area. The one or more microfluidic channels are configured to allow flow of a plurality of blood cells of a blood sample within an interior surface of the one or more microfluidic channels. Further, at least one imager is configured to generate one or more digital holography images or videos of the plurality of blood cells transiting the one or more microfluidic channels. Further, at least one processor is configured to receive the one or more digital holography images or videos and analyze the generated one or more digital holography images or videos to quantify and/or characterize occlusions formed within the one or more microfluidic channels.
G01N 33/80 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood groups or blood types
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means
64.
SYSTEMS, APPARATUSES, AND METHODS TO MEASURE ADHESION OF BLOOD CELLS IN MICROFLUIDIC CHANNELS
A system and a method for measuring adhesion of blood cells in microfluidic channels are disclosed. The system includes a device having one or more microfluidic channels configured to adhere a plurality of diseased red blood cells (RBCs) of a blood sample on an interior surface of the one or more microfluidic channels. Further, the system includes at least one imager configured to generate one or more digital holography images or videos of the plurality of diseased RBCs adhered to the interior surface of the one or more microfluidic channels. Further, at least one processor is operationally coupled to the at least one imager and configured to receive the one or more digital holography images or videos and analyze the generated one or more digital holography images or videos to quantify adhesion of the plurality of diseased RBCs to the interior surface of the one or more microfluidic channels.
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
G01N 33/49 - Physical analysis of biological material of liquid biological material blood
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 30/00 - ICT specially adapted for the handling or processing of medical images
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
65.
MULTIPLEXED-TARGETED ADENOVIRUS VECTORS AND THEIR USE
The present application provides compositions and methods for increasing safety, selectivity, and efficacy of transduction of human cells, including human long-term repopulating and hematopoietic stem cells (LT-HSC) and human cancer cells, by adenovirus vectors through multiplexed targeting of virus attachment and internalization receptors. Multiplexing targeting Ad vector receptor specificities through the combination of i) restricting fiber-specific attachment receptors, ii) deleting the RGD amino acid motif from the penton base protein, and iii) inserting into Ad penton base protein of peptides that lack the RGD amino acid motif and enable vector interaction with integrin classes expressed on target cells, allows for the improvement of safety, selectivity, and efficacy of vector-mediated transduction of human cells in vitro and after intravenous vector administration in vivo.
A smartphone-based hemoglobin (Hgb) assessment application quantitatively analyzes pallor in patient-sourced photos using image analysis algorithms to enable a noninvasive, accurate quantitative smartphone app for detecting anemia. A user takes a photo of his/her fingernail beds using the app and receives an accurate displayed Hgb level. Since fingernails do not contain melanocytes, the primary source of color of these anatomical features is blood Hgb. At the same time, quality control software minimizes the impact of common fingernail irregularities (e.g. leukonychia and camera flash reflection) on Hgb level measurement. Metadata recorded upon capturing the image is leveraged for determining a users' Hgb level thereby eliminating the need for external equipment. A personalized calibration of image data with measured Hgb levels improves the accuracy of the application.
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/103 - Measuring devices for testing the shape, pattern, size or movement of the body or parts thereof, for diagnostic purposes
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
Disclosed herein are double stranded therapeutic oligonucleotide endosomal escape peptide conjugates and uses in therapeutic methods. In certain embodiments, the double stranded therapeutic oligonucleotide endosomal escape peptide conjugate comprises a pH sensitive polynucleotide strand and a therapeutic polynucleotide strand. In certain embodiments, the therapeutic polynucleotide strand is conjugated to an endosomal escape peptide (EEP). In certain embodiments, the double stranded therapeutic oligonucleotide endosomal escape peptide conjugate is attached to a particle. In certain embodiments, the double stranded therapeutic oligonucleotide endosomal escape peptide conjugate or coated particle is used in an antisense or other oligonucleotide therapy.
The present disclosure relates to methods for inducing intracranial tumor in a non-human animal. The disclosure also relates to an intracranial cancer engineered non-human animal model with a combination of viral vectors encoding oncogenes or shRNA targeting tumor suppressor genes and a population of intracranial cancer cells derived therefrom.
Disclosed herein are methods for preventing or treating a viral infection, e.g., coronavirus, enterovirus, norovirus, picornavirus, rhinovirus, and/or a herpes virus infection. In certain embodiments, this disclosure relates to peptidomimetic heterocyclic compounds and pharmaceutical compositions comprising the same for uses in methods disclosed herein.
The present disclosure relates to a method. The method includes accessing first imaging data having a first imaging modality. The first imaging data includes first radiological images from patients that have experienced a first outcome and second radiological images from patients that have experienced a second outcome. A first SOI is identified from the first imaging data. The first SOI has shape and/or area differences between the first and second radiological images. Second imaging data having a second imaging modality is accessed. The second imaging data includes third radiological images from patients that have experienced the first outcome and fourth radiological images from patients that have experienced the second outcome. A second SOI is identified from the second imaging data. The second SOI has shape and/or area differences between the third and fourth radiological images. A corroborated SOI is generated by identifying spatial corroboration between the first and second SOI.
Methods for preparing 3-azabicyclo[3.1.0]hexane-6-carboxamide derivatives, which can be useful as SSTR4 agonist compounds. Methods for preparing 3-azabicyclo[3.1.0]hexane-6-carboxamide derivatives through a rhodium catalyzed cyclopropanation reaction with alkyl diazoacetate under low catalyst loadings. Methods for preparing 3-azabicyclo[3.1.0]hexane-6-carboxamide derivatives including a isomerization step and/or a selective hydrolysis step. Methods for preparing an intermediate compound through a rhodium catalyzed cyclopropanation reaction with alkyl diazoacetate under low catalyst loadings, which can be useful in the preparation of a variety of 3-azabicyclo[3.1.0]hexane-6-carboxamide derivatives.
C07D 209/52 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
This disclosure relates to compositions and methods of treating disorders such as cancer using immune effector cells (e.g., T cells or NK cells) that express a chimeric antigen receptor (CAR). In certain embodiment, this disclosure relates to methods of using a CAR-expressing cell therapy in combination with a vasoactive intestinal peptide receptor antagonist.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
73.
Fumaric Acid Esters, Inhalation Administration Methods, Pharmaceutical Uses and Compositions
Arizona Board of Regents on behalf of the University of Arizona (USA)
Inventor
Hecker, Louise
Kato, Kosuke
Mansour, Heidi M.
Muralidharan, Priyadarshini
Abstract
This disclosure relates to uses of fumaric acid, fumaric acid esters, dimethyl fumarate, monomethyl fumarate ester, salt, or derivatives thereof by pulmonary administration in the treatment, prevention, or reversal of fibrosis e.g., pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF). In certain embodiments, this disclosure relates to treating a subject with fumaric acid, fumaric acid esters, dimethyl fumarate, monomethyl fumarate ester, salt, or derivatives inhibiting TGF-mediated pro-fibrotic phenotypes. In certain embodiments, the subject is a human of an advanced age.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 11/00 - Drugs for disorders of the respiratory system
74.
Methods For Prevention Of Graft Rejection In Xenotransplantation
The present invention relates to methods, treatment regimens, uses, kits and therapies for prevention of graft rejection in solid organ transplantation, particularly solid organ xenotransplantation, by administering an anti-CD40 antibody or a combination of an anti-CD40 antibody and an anti-C5 antibody.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/36 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
75.
METHODS FOR ANALYZING IMMUNE RESPONSES AND ANTIGEN PROFILING
This invention relates to a method for testing the immune response of a subject to at least one antigen. The inventive method also enables screening for immunogenic antigens, selecting subjects for specific regimens based on the tested immune response and identifying or isolating T cells, which specifically recognize antigens in a subject.
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
76.
FORMULATION OF A RILUZOLE SOLUTION WITH BETA-CYCLODEXTRINS
This disclosure relates to methods and compositions for labeling, isolating, detecting, measuring, and purifying tertiary amines. In certain embodiments, the tertiary amine has a dimethyl amine such as in the case of dimethyl lysine, and N-terminal dimethyl amino groups in peptides. In certain embodiments, this disclosure relates to methods of labeling, isolating, detecting, measuring, and purifying compounds having tertiary amines, dimethyl lysines, or N-terminal dimethyl amines in proteins, or nucleic acids containing the same from a sample optionally utilizing solid supports.
University Hospitals Cleveland Medical Center (USA)
Inventor
Shiradkar, Rakesh
Midya, Abhishek
Madabhushi, Anant
Ponsky, Lee E.
Abstract
The present disclosure, in some embodiments, relates to a method. The method includes accessing one or more digitized images of a cancer patient of a first population. One or more regions of interest are identified within the one or more digitized images. A plurality of population specific features are extracted from the one or more regions of interest within the one or more digitized images. The plurality of population specific features are features that have been identified as being prognostic of an outcome for patients of the first population. A population specific machine learning model is operated upon the plurality of population specific features to generate a medical prediction relating to the outcome.
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
79.
COMPOSITIONS AND USES OF VASOACTIVE INTESTINAL PEPTIDE (VIP) ANTAGONISTS
This disclosure relates to VIP antagonist for uses in managing the treatment or prevention of cancer and viral infections. In certain embodiments, this disclosure relates to chimeric variants of VIP antagonists, as peptides disclosed herein, and pharmaceutical composition comprising the same. In certain embodiments, this disclosure contemplates methods of stimulating immune cells to target cancer by mixing immune cells in vitro with peptides disclosed herein and further administering an effective amount of stimulated immune cells to a subject in need of cancer treatment.
This disclosure relates to targeted protease compositions and uses related thereto. In certain embodiments, the disclosure relates to nanoparticles wherein a targeting molecule is linked to the nanoparticle and wherein a catalytic domain of a protease is linked to the nanoparticle. In certain embodiments, the targeting molecule and the catalytic domain are within a single polypeptide sequence. In certain embodiments, the targeting molecule binds a molecule more highly expressed on cancer cells then non-cancerous cells, and the nanoparticles disclosed herein are used for the treatment of cancer by further attaching an anti-cancer agent to the nanoparticle or incorporating an anticancer agent within the nanoparticle.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
Compounds, compositions and methods for preventing, treating or curing a coronavirus infection in human subjects or other animal hosts. In one embodiment, the compounds can be used to treat an infection with a severe acute respiratory syndrome virus, such as human coronavirus 229E, SARS, MERS, SARS-CoV-1, OC43, and SARS-CoV-2. In another embodiment, the methods are used to treat a patient infected with a Flavivirus, Picornavus, Togavirus, or Bunyavirus.
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present disclosure relates to a method. The method includes operating a first spatiotemporal model upon a plurality of frames of an anatomic video of a patient to determine a first prediction. The first spatiotemporal model is configured to determine the first prediction using a plurality of hand-crafted features extracted from the plurality of frames. A second spatiotemporal model having one or more deep learning models is operated upon the plurality of frames of the anatomic video to determine a second prediction. A medical prediction is generated based upon a combination of the first prediction and the second prediction.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Disclosed herein are method of vaccinating or treating a subject for a hepatitis C virus. In certain embodiments, methods comprise administering to a subject a DNA plasmid encoding hepatitis C virus core, E1, E2, and/or p7 proteins. In certain embodiments, methods further comprise administering a recombinant attenuated vaccinia vector encoding hepatitis C virus non-structural NS3, NS4a, NS4b, NS5a and/or NS5b proteins. In certain embodiments, the subject is a human subject.
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
This disclosure relates to methods of treating bronchiectasis comprising administering an effective amount of a cystic fibrosis drug to a subject. In certain embodiments, the subject is diagnosed with non-CF bronchiectasis and the subject is diagnosed with moderate elevated sweat chloride and optionally pancreatic sufficiency. In certain embodiments, a sample of the subject is tested for presence of a known cystic fibrosis transmembrane conductance regulator mutation and no mutation is identified in the sample, thereby providing a subject diagnosed without a known cystic fibrosis transmembrane conductance regulator mutation. In certain embodiments, this disclosure relates to methods of bronchiectasis treatment by managing symptoms such as slowing decline in lung function and preventing exacerbations.
A61K 31/443 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 11/00 - Drugs for disorders of the respiratory system
86.
TRANSFORMER-BASED MULTI-MODAL AND MULTI-REGION DATA FUSION FRAMEWORK
The present disclosure relates to a method. The method includes applying one or more multi-stage hierarchical transformations on data corresponding to one or more first regions of interest (ROIs) within a digitized pathology image of a patient to generate a pathology feature map and on data corresponding to one or more second ROIs from a radiological image of the patient to generate a radiology feature map. Respective stages of the one or more multi-stage hierarchical transformations comprise a self-attention operation. The radiology feature map and the pathology feature map are combined to generate a fused feature map. The fused feature map is operated upon with a machine learning model to generate one or more medical predictions for the patient.
This disclosure relates to agents such as antisense oligonucleotides which bind nucleic acids encoding cryptic exons suppressing or preventing cryptic splicing of ELAVL3 and uses in treating or preventing TDP-43 related neurodegenerative or neurological diseases or conditions relates thereto. In certain embodiments, the antisense oligonucleotide is a nucleobase polymer capable of decreasing cellular levels of or expression of ELAVL3 cryptic exon RNA and increasing or restoring functional ELAVL3 protein expression substantially excluding cryptic exon RNA peptide sequence incorporation.
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61P 25/00 - Drugs for disorders of the nervous system
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
Phosphate prodrugs of cannabinoids are disclosed herein as are pharmaceutical compositions comprising one or more of the same. Such compounds and compositions are useful for the treatment of diseases, disorders, and/or conditions, including neurological disorders and neuropathic pain.
An exemplary robotic needle insertion system is disclosed that can provide respiration compensated needle insertion for an accurate and efficient ablation, biopsy, draining placement of a needle, among other surgical procedures. The system employs a robotic instrument comprising (i) a needle insertion mechanism configured to deliver the needle insertion in a step-wise manner that mimics the current clinical practice by inserting the needle (e.g., RFA needle) according to respiration and other motion and (ii) a probe manipulation mechanism to direct an ultrasound probe to provide intraoperative image guidance for the needle insertion. The robotic instrument includes a multi-degrees of freedom (DoF) motion control and actuator to provide for the accurate targeting of the needle at any workspace location
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
Inventor
Wan, Yong
Zhu, Yueming
Bahar, Ivet
Banerjee, Anupam
Lee, Jiyoung
Abstract
Disclosed herein are pharmaceutical agents that inhibit or suppress OTUD4 and CD73 binding interactions; thus, useful in the context of managing diseases and conditions associated with OTUD4 and CD73 binding interactions, such as cancer treatments. In certain embodiments, this disclosure relates to method of treating cancer comprising administering an effective amount of a pharmaceutical agent that suppress OTUD4 and CD73 binding interactions. In certain embodiments, the therapeutic agent is a small molecule, antibody, or other specific binding agent.
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (USA)
EMORY UNIVERSITY (USA)
Inventor
Krammer, Florian
Palese, Peter
Garcia-Sastre, Adolfo
Pardi, Norbert
Amara, Rama Rao
Ahmed, Rafi
Turner-Styles, Tiffany
Akhtar, Akil
Abstract
Provided herein are nucleoside-modified mRNA molecules encoding a chimeric influenza virus hemagglutinin (HA) polypeptide, wherein the chimeric influenza virus HA polypeptide comprises an influenza virus HA globular head domain and an influenza virus HA stalk domain, and wherein the influenza virus HA globular head domain is heterologous to the influenza virus HA stalk domain. Also provided herein are lipid nanoparticle compositions comprising a lipid component and a nucleoside-modified mRNA molecule encoding a chimeric influenza virus polypeptide, wherein the chimeric influenza virus HA polypeptide comprises an influenza virus HA globular head domain and an influenza virus HA stalk domain, and wherein the influenza virus HA globular head domain is heterologous to the influenza virus HA stalk domain. Further provided herein are methods of immunizing a subject against influenza virus disease and methods of preventing influenza virus disease in a subject using a composition described herein (e.g., a lipid nanoparticle composition described herein).
This disclosure relates to compounds, compositions, and methods for managing cancer treatment using Indolium compounds and salts thereof as disclosed herein. In certain embodiments, this disclosure relates to treating or preventing cancer comprising administering an effective amount 3-(bis(4-(diethylamino)phenyl) methylene)-1-methyl-2-phenyl-3H-indol-1-ium (Indolium-1), salt or derivative thereof to a subject in need thereof, optionally in combination with another anticancer agent. In certain embodiments, the cancer is a melanoma. In certain embodiments, this disclosure relates to pharmaceutical compositions having Indolium compounds and salts thereof.
An exemplary system and method that non-invasively assess the effusion state of a joint via the use of a non-invasive measurement device. The measurement device actively interrogates the bone connected to the joint and nearby tissue with mechanical or acoustic energy by applying an impulse or vibratory mechanical or acoustic energy into the bone to assess the response of the bone at its connecting joint and its proximate tissue. The measurement device may additionally interrogate the bone connected to the joint and nearby tissue with electrical energy by applying an impulse or vibratory electrical energy into the joint (e.g., knee) or its nearby tissue to assess the electrical response of the joint and its proximate tissue. In some embodiments, the sensors employ both mechanical interrogation and electrical interrogation of the joint for the non-invasive assessment, e.g., for bioimpedance characteristics of the tissue and joint.
The systems and methods are directed to leveraging the channel geometry and configuration to overcome diffusion limitations of current transduction systems. The methods may include a method of transducing target cells using a device. The device may include at least one continuous channel. The method may include delivering target cells and viral vectors into a transduction region of the channel. After transducing for some incubation time, a flushing solution may be delivered. The method may include collecting transduced cells after the transducing incubation time and the delivering of the flushing solution.
Disclosed herein are dirhodium tetrakis(binaphthylphosphate) complexes for uses in catalyzing synthetic processes. In certain embodiments, this disclosure relates to compositions comprising dirhodium tetrakis(binaphthylphosphate) complexes disclosed herein. In certain embodiments, this disclosure relates to methods of making compounds disclosed herein by contacting compounds with catalytic dirhodium tetrakis(binaphthylphosphate) complexes disclosed herein.
This disclosure contemplates recombinant oligomannose binding lectins reported herein. In certain embodiments, this disclosure contemplates uses of recombinant oligomannose binding lectins disclosed herein for purification and detection methods. In certain embodiments, this disclosure contemplates uses of recombinant oligomannose binding lectins disclosed herein for treating or preventing viral infections, cancer, or other immunological diseases or conditions. In certain embodiments, this disclosure relates to pharmaceutical compositions comprising recombinant oligomannose binding lectins disclosed herein or nucleic acid or vector encoding the same.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 39/00 - Medicinal preparations containing antigens or antibodies
Disclosed herein are hydrogels containing a nucleic acid based polymer matrix and optionally cargo. In certain embodiments, a CRISPR nuclease, such as Cas12a, is dispersed within the hydrogel for the purpose of selectively cleaving nucleic acid based unfolded single strands of originally crosslinked hairpins leading to hydrogel degradation. The hydrogels may be designed to respond to piconewton-scale forces, enabling potential applications in mechanically-triggered drug delivery and force sensing in cellular environments.
The devices, systems, and methods can improve magnetic resonance imaging (MRI), MR spectroscopy (MRS), MR spectroscopic imaging (MRSI) measurement(s), thereby providing more reliable quantification. The method may include a method for correcting MR image(s)/spectrum. The method may include providing an inhomogeneity field/response map of a region of interest; and providing MR image(s)/spectrum of the region of interest. The method may include determining an intravoxel/voxel inhomogeneity correction coefficient for each voxel of at least one subregion of the region of the interest using the inhomogeneity field/response map. The method may include correcting each voxel of the MR image(s)/spectrum of the region of interest using the intravoxel/voxel inhomogeneity correction coefficient. The MR image(s)/spectrum may include chemical exchange saturation transfer (CEST)/magnetization transfer (MT) imaging with Z-spectrum, CEST/MT imaging without Z-spectrum, CEST spectroscopy, CEST MRS, MRS, MRSI, or any combination thereof.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G01R 33/44 - Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
G01R 33/483 - NMR imaging systems with selection of signal or spectra from particular regions of the volume, e.g. in vivo spectroscopy
G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
G06V 10/25 - Determination of region of interest [ROI] or a volume of interest [VOI]
G06V 10/98 - Detection or correction of errors, e.g. by rescanning the pattern or by human interventionEvaluation of the quality of the acquired patterns
99.
SYSTEM AND METHODS FOR AUTOMATED DEEP BRAIN STIMULATION PARAMETER SELECTION VIA META-ACTIVE LEARNING OF EVOKED POTENTIALS
An exemplary embodiment of the present disclosure provides a system for generating a set of stimulation parameters, the system comprising at least one processor and a memory in communication with the at least one processor and having stored thereon instructions that, when executed by the at least one processor, is configured to cause the system to analyze, using a machine learning model, data from the deep brain stimulation device or an electromyography and generate, in response to analyzing, at least in part, the data, a set of stimulation parameters for deep brain stimulation.
Embodiments described herein relate to an implant delivery system for delivering an implant for reducing heart valve regurgitation. The implant delivery system may include an implant catheter disposed in an inner lumen of a guide catheter. The implant catheter may include one or more hypotubes disposed therein, each hypotube configured to receive an elongate member such as a braided tether. A distal end of the implant catheter may be coupled to an implant holder configured to receive the implant. The implant holder may define one or more channels, each channel configured to receive a portion of a respective elongate member. The elongate members configured to couple the implant to the implant holder and transition the implant between configurations. The implant configured to be disposed around a portion of a leaflet of a heart valve to improve coaptation of the heart valve.
